Buprenorphine Explained

Verifiedfields:changed
Watchedfields:changed
Verifiedrevid:457118559
Width:220
Width2:220
Alt2:Ball-and-stick model of the buprenorphine molecule
Pronounce:bew-pre-nor-feen
Tradename:Subutex, Sublocade, Brixadi, others
Dailymedid:Buprenorphine
Pregnancy Au:C
Pregnancy Au Comment:[1] [2]
Dependency Liability:Psychological

High Physical: Moderate[3]

Routes Of Administration:Sublingual, buccal, intramuscular, intravenous, transdermal, intranasal, rectally, subcutaneous
Atc Prefix:N02
Atc Suffix:AE01
Legal Au:S8
Legal Br:A1
Legal Br Comment:[4]
Legal Ca:Schedule I
Legal Ca Comment:[5] [6]
Legal De:Anlage III
Legal Uk:Class C
Legal Us:Schedule III
Legal Us Comment:[7] [8] [9] [10] [11]
Legal Eu:Rx-only
Legal Eu Comment:[12]
Legal Un:P III
Bioavailability:Sublingual: 30%[13]
Intranasal: 48%[14]
Buccal: 65%[15] [16]
Protein Bound:96%
Metabolism:Liver (CYP3A4, CYP2C8)
Onset:Within 30 min
Elimination Half-Life:37 hours (range 20–70 hours)
Duration Of Action:Up to 24 hrs
Excretion:Bile duct and kidney
Cas Number:52485-79-7
Pubchem:644073
Iuphar Ligand:1670
Drugbank:DB00921
Chemspiderid:559124
Unii:40D3SCR4GZ
Kegg:D07132
Chebi:3216
Chembl:511142
Iupac Name:(2S)-2-[(5''R'',6''R'',7''R'',14''S'')-17-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylbutan-2-ol
C:29
H:41
N:1
O:4
Smiles:Oc7ccc5c1c7O[C@H]3[C@]6(OC)[C@H](C[C@@]2([C@H](N(CC[C@@]123)CC4CC4)C5)CC6)[C@@](O)(C)C(C)(C)C
Stdinchi:1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1
Stdinchikey:RMRJXGBAOAMLHD-IHFGGWKQSA-N

Buprenorphine, sold under the brand name Subutex among others, is an opioid used to treat opioid use disorder, acute pain, and chronic pain. It can be used under the tongue (sublingual), in the cheek (buccal), by injection (intravenous and subcutaneous), as a skin patch (transdermal), or as an implant.[17] For opioid use disorder, the patient must have moderate opioid withdrawal symptoms before buprenorphine can be administered under direct observation of a health-care provider.

In the United States, the combination formulation of buprenorphine/naloxone (Suboxone) is usually prescribed to discourage misuse by injection. However, more recently the efficacy of naloxone in preventing misuse has been brought into question, and preparations of buprenorphine combined with naloxone could potentially be less safe than buprenorphine alone.[18] Maximum pain relief is generally within an hour with effects up to 24 hours. Buprenorphine affects different types of opioid receptors in different ways. Depending on the type of opioid receptor, it may be an agonist, partial agonist, or antagonist. Buprenorphine's activity as an agonist/antagonist is important in the treatment of opioid use disorder: it relieves withdrawal symptoms from other opioids and induces some euphoria, but also blocks the ability for many other opioids, including heroin, to cause an effect. Unlike full agonists like heroin or methadone, buprenorphine has a ceiling effect, such that taking more medicine past a certain point will not increase the effects of the drug.[19]

Side effects may include respiratory depression (decreased breathing), sleepiness, adrenal insufficiency, QT prolongation, low blood pressure, allergic reactions, constipation, and opioid addiction.[20] Among those with a history of seizures, a risk exists of further seizures. Opioid withdrawal following stopping buprenorphine is generally less severe than with other opioids. Whether use during pregnancy is safe is unclear, but use while breastfeeding is probably safe, since the dose the infant receives is 1-2% that of the maternal dose, on a weight basis.[21]

Buprenorphine was patented in 1965, and approved for medical use in the United States in 1981.[22] [23] It is on the World Health Organization's List of Essential Medicines.[24] In addition to prescription as an analgesic it is a common medication used to treat opioid use disorders, such as addiction to heroin. In 2020, it was the 186th most commonly prescribed medication in the United States, with more than 2.8million prescriptions.[25] [26] Buprenorphine may also be used recreationally for the high it can produce. In the United States, buprenorphine is a schedule III controlled substance.[27]

Medical uses

Opioid use disorder

Buprenorphine is used to treat people with opioid use disorder.[28] In the U.S., the combination formulation of buprenorphine/naloxone is generally prescribed to deter injection, since naloxone, an opioid antagonist, is believed to cause acute withdrawal if the formulation is crushed and injected.[29] Taken orally, the naloxone has virtually no effect, due to the drug's extremely high first-pass metabolism and low bioavailability (2%).[30] However, the efficacy of naloxone in preventing misuse by injection has more recently been brought into question and preparations including naloxone could even be less safe than preparations containing solely buprenorphine. Anecdotally, posters on drug-related online forums have stated that they were able to attain a high by injecting preparations of buprenorphine despite being combined with naloxone.

Before starting buprenorphine, individuals are generally advised to wait long enough after their last dose of opioid until they have some withdrawal symptoms to allow for the medication to bind the receptors, since if taken too soon, buprenorphine can displace other opioids bound to the receptors and precipitate an acute withdrawal. The dose of buprenorphine is then adjusted until symptoms improve, and individuals remain on a maintenance dose of 8–16 mg. Because withdrawal is uncomfortable and a deterrent for many patients, many have begun to call for different means of treatment initiation.[31] Some providers have begun to use the Bernese method, also known as microdosing, in which very small doses of buprenorphine are given while patients are still using street opioids, and without precipitating withdrawal, with medicine levels slowly titrated upward.[32] [33]

Buprenorphine versus methadone

Both buprenorphine and methadone are medications used for detoxification and opioid replacement therapy, and appear to have similar effectiveness based on limited data.[34] Both are safe for pregnant women with opioid use disorder, although preliminary evidence suggests that methadone is more likely to cause neonatal abstinence syndrome.[35] In the US and European Union, only designated clinics can prescribe methadone for opioid use disorder, requiring patients to travel to the clinic daily. If patients are drug free for a period they may be permitted to receive "take home doses," reducing their visits to as little as once a week. Alternatively, up to a month's supply of buprenorphine has been able to be prescribed by clinicians in the US or Europe who have completed a basic training (8–24 hours in the US) and received a waiver/licence allowing prescription of the medicine. In France, buprenorphine prescription for opioid use disorder has been permitted without any special training or restrictions since 1995, resulting in treatment of approximately ten times more patients per year with buprenorphine than with methadone in the following decade.[36] In 2021, seeking to address record levels of opioid overdose, the United States also removed the requirement for a special waiver for prescribing physicians.[37] Whether this change will be sufficient to impact prescription is unclear, since even before the change as many as half of physicians with a waiver permitting them to prescribe buprenorphine did not do so, and one third of non-waivered physicians reported that nothing would induce them to prescribe buprenorphine for opioid use disorder.[38]

Chronic pain

A transdermal patch is available for the treatment of chronic pain.[22] These patches are not indicated for use in acute pain, pain that is expected to last only for a short period of time, or pain after surgery, nor are they recommended for opioid addiction.[39]

Potency

With respect to equianalgesic dosing, when used sublingually, the potency of buprenorphine is about 40 to 70 times that of morphine.[40] [41] When used as a transdermal patch, the potency of buprenorphine may be 100 to 115 times that of morphine.[42] [43]

Adverse effects

Common adverse drug reactions associated with the use of buprenorphine, similar to those of other opioids, include nausea and vomiting, drowsiness, dizziness, headache, memory loss, cognitive and neural inhibition, perspiration, itchiness, dry mouth, shrinking of the pupils of the eyes (miosis), orthostatic hypotension, male ejaculatory difficulty, decreased libido, and urinary retention. Constipation and central nervous system (CNS) effects are seen less frequently than with morphine.[44] Central sleep apnea has also been reported as a side effect of long-term buprenorphine use.[45] [46]

Respiratory effects

The most severe side effect associated with buprenorphine is respiratory depression (insufficient breathing).[22] It occurs more often in those who are also taking benzodiazepines or alcohol, or have underlying lung disease.[22] The usual reversal agents for opioids, such as naloxone, may be only partially effective, and additional efforts to support breathing may be required.[22] Respiratory depression may be less than with other opioids, particularly with chronic use.[47] In the setting of acute pain management, though, buprenorphine appears to cause the same rate of respiratory depression as other opioids such as morphine.[48] Central sleep apnea is possible with long-term use, possibly resolving with dose reduction.

Buprenorphine dependence

Buprenorphine treatment carries the risk of causing psychological or physiological (physical) dependencies. It has a slow onset of activity, with a long duration of action, and a long half-life of 24 to 60 hours. Once a patient has stabilised on the (buprenorphine) medication and programme, three options remain - continual use (buprenorphine-only medication), switching to a buprenorphine/naloxone combination, or a medically supervised withdrawal.[47]

Pain management

Achieving acute opioid analgesia is difficult in persons using buprenorphine for pain management.[49] However, a systematic review found no clear benefit to bridging or stopping buprenorphine when used in opioid substitution therapy to facilitate perioperative pain management, but failure to restart it was found to pose concerns for relapse. Therefore, it is recommended that buprenophine opioid substitution therapy is continued in the perioperative period when possible. In addition preoperative pain management in patients taking buprenorphine should use an interdisciplinary approach with multimodal analgesia.[50]

Pharmacology

Pharmacodynamics

Buprenorphine[51]
Site Ki (nM) Action Species Stimulation Ref
0.7-2.3
0.081 		Partial agonist Human
Monkey 		38%±10[52] [53] [54]
[55]
2.9–6.1
0.82 		Antagonist Human
Monkey 		0[56]
0.62–2.5
0.44 		Antagonist/weak partial agonist (dose and source dependent) Human
Monkey 		9%±5
77.4 Partial agonist Human 50±10(8mg≥)
>100,000 [57]
>10,000 Agonist Human [58]
>100,000 Rat [59]
>100,000 Rat
33,000 (IC50) Inhibitor Rodent [60]
Values are Ki (nM), unless otherwise noted. The smaller
the value, the more strongly the drug binds to the site.

Opioid receptor modulator

Buprenorphine has been reported to possess these following pharmacological activities:

In simplified terms, buprenorphine can essentially be thought of as a nonselective, mixed agonist–antagonist opioid receptor modulator,[67] acting as an unusually high affinity, weak partial agonist of the MOR, a high affinity antagonist of the KOR and DOR, and a relatively low affinity, very weak partial agonist of the ORL-1/NOP.[68] [69] [70] [71] [72]

Although buprenorphine is a partial agonist of the MOR, human studies have found that it acts like a full agonist with respect to analgesia in opioid-intolerant individuals.[73] Conversely, buprenorphine behaves like a partial agonist of the MOR with respect to respiratory depression.

Buprenorphine is also known to bind to with high affinity and antagonize the putative ε-opioid receptor.[74] [75]

Full analgesic efficacy of buprenorphine requires both exon 11-[76] and exon 1-associated μ-opioid receptor splice variants.[77]

The active metabolites of buprenorphine are not thought to be clinically important in its CNS effects.[73]

In positron emission tomography (PET) imaging studies, buprenorphine was found to decrease whole-brain MOR availability due to receptor occupancy by 41% (i.e., 59% availability) at 2 mg, 80% (i.e., 20% availability) at 16 mg, and 84% (i.e., 16% availability) at 32 mg.[78] [79] [80] [81]

Other actions

Unlike some other opioids and opioid antagonists, buprenorphine binds only weakly to and possesses little if any activity at the sigma receptor.[82] [83]

Buprenorphine also blocks voltage-gated sodium channels via the local anesthetic binding site, and this underlies its potent local anesthetic properties.

Similarly to various other opioids, buprenorphine has also been found to act as an agonist of the toll-like receptor 4, albeit with very low affinity.

Pharmacokinetics

Buprenorphine is metabolized by the liver, via CYP3A4 (also CYP2C8 seems to be involved) isozymes of the cytochrome P450 enzyme system, into norbuprenorphine (by N-dealkylation). The glucuronidation of buprenorphine is primarily carried out by UGT1A1 and UGT2B7, and that of norbuprenorphine by UGT1A1 and UGT1A3. These glucuronides are then eliminated mainly through excretion into bile. The elimination half-life of buprenorphine is 20 to 73 hours (mean 37 hours). Due to the mainly hepatic elimination, no risk of accumulation exists in people with renal impairment.[84]

One of the major active metabolites of buprenorphine is norbuprenorphine, which, in contrast to buprenorphine itself, is a full agonist of the MOR, DOR, and ORL-1, and a partial agonist at the KOR.[85] [86] However, relative to buprenorphine, norbuprenorphine has extremely little antinociceptive potency (1/50th that of buprenorphine), but markedly depresses respiration (10-fold more than buprenorphine).[87] This may be explained by very poor brain penetration of norbuprenorphine due to a high affinity of the compound for P-glycoprotein. In contrast to norbuprenorphine, buprenorphine and its glucuronide metabolites are negligibly transported by P-glycoprotein.

The glucuronides of buprenorphine and norbuprenorphine are also biologically active, and represent major active metabolites of buprenorphine.[88] Buprenorphine-3-glucuronide has affinity for the MOR (Ki = 4.9 pM), DOR (Ki = 270 nM) and ORL-1 (Ki = 36 μM), and no affinity for the KOR. It has a small antinociceptive effect and no effect on respiration. Norbuprenorphine-3-glucuronide has no affinity for the MOR or DOR, but does bind to the KOR (Ki = 300 nM) and ORL-1 (Ki = 18 μM). It has a sedative effect but no effect on respiration.

Chemistry

Buprenorphine is a semisynthetic derivative of thebaine,[89] and is fairly soluble in water, as its hydrochloride salt. It degrades in the presence of light.

Detection in body fluids

Buprenorphine and norbuprenorphine may be quantified in blood or urine to monitor use or non-medical recreational use, confirm a diagnosis of poisoning, or assist in a medicolegal investigation. A significant overlap of drug concentrations exists in body fluids within the possible spectrum of physiological reactions ranging from asymptomatic to comatose. Therefore, having knowledge of both the route of administration of the drug and the level of tolerance to opioids of the individual is critical when results are interpreted.[90]

History

In 1969, researchers at Reckitt and Colman (now Reckitt Benckiser) had spent 10 years attempting to synthesize an opioid compound "with structures substantially more complex than morphine [that] could retain the desirable actions whilst shedding the undesirable side effects". Physical dependence and withdrawal from buprenorphine itself remain important issues, since buprenorphine is a long-acting opioid.[91] Reckitt found success when researchers synthesized RX6029 which had showed success in reducing dependence in test animals. RX6029 was named buprenorphine and began trials on humans in 1971.[92] [93] By 1978, buprenorphine was first launched in the UK as an injection to treat severe pain, with a sublingual formulation released in 1982.

Society and culture

Regulation

United States

In the United States, buprenorphine and buprenorphine with naloxone were approved for opioid use disorder by the Food and Drug Administration in October 2002.[94] The DEA rescheduled buprenorphine from a schedule V drug to a schedule III drug just before approval.[95] The ACSCN for buprenorphine is 9064, and being a schedule III substance, it does not have an annual manufacturing quota imposed by the DEA.[96] The salt in use is the hydrochloride, which has a free-base conversion ratio of 0.928.

In the years before buprenorphine/naloxone was approved, Reckitt Benckiser had lobbied Congress to help craft the Drug Addiction Treatment Act of 2000, which gave authority to the Secretary of Health and Human Services to grant a waiver to physicians with certain training to prescribe and administer schedule III, IV, or V narcotic drugs for the treatment of addiction or detoxification. Before this law was passed, such treatment was permitted only in clinics designed specifically for drug addiction.[97]

The waiver, which can be granted after the completion of an eight-hour course, was required for outpatient treatment of opioid addiction with buprenorphine from 2000 to 2021. Initially, the number of people each approved physician could treat was limited to 10. This was eventually modified to allow approved physicians to treat up to 100 people with buprenorphine for opioid addiction in an outpatient setting.[98] This limit was increased by the Obama administration, raising the number of patients to which doctors can prescribe to 275.[99] On 14 January 2021, the US Department of Health and Human Services announced that the waiver would no longer be required to prescribe buprenorphine to treat up to 30 people concurrently.[100]

New Jersey authorized paramedics to give buprenorphine to people at the scene after they have recovered from an overdose.[101]

Europe

In the European Union, Subutex and Suboxone, buprenorphine's high-dose sublingual tablet preparations, were approved for opioid use disorder treatment in September 2006.[102] In the Netherlands, buprenorphine is a list II drug of the Opium Law, though special rules and guidelines apply to its prescription and dispensation. In France, where buprenorphine prescription by general practitioners and dispensed by pharmacies has been permitted since the mid-1990s as a response to HIV and overdose risk. Deaths caused by heroin overdose were reduced by four-fifths between 1994 and 2002, and incidence of AIDS among people who inject drugs in France fell from 25% in the mid-1990s to 6% in 2010.[103]

Brand names

Buprenorphine is available under the brand names Cizdol, Brixadi (approved in the US by FDA for addiction treatment in 2023), Suboxone (with naloxone), Subutex (typically used for opioid use disorder), Zubsolv, Bunavail, Buvidal (approved in the UK, Europe and Australia for addiction treatment in 2018), Sublocade (approved in the US in 2018),[104] [105] [106] Probuphine, Temgesic (sublingual tablets for moderate to severe pain), Buprenex (solutions for injection often used for acute pain in primary-care settings), Norspan, and Butrans (transdermal preparations used for chronic pain).[107] In Poland buprenorphine is available under the trade names Bunondol (for pain treatment, when morphine is too little; amounts of 0.2mg and 0.4mg) and Bunorfin (for addicts substitution in amount of 2 and 8mg).

Research

Microdosing

There is some evidence that a buprenorphine microdosing regime, started before opioid withdrawal symptoms have started, can be effective in helping people transitioning away from opioid dependence.[108]

Depression

Some evidence supports the use of buprenorphine for depression.[109] Buprenorphine/samidorphan, a combination product of buprenorphine and samidorphan (a preferential μ-opioid receptor antagonist), appears useful for treatment-resistant depression.[110]

Cocaine dependence

In combination with samidorphan or naltrexone (μ-opioid receptor antagonists), buprenorphine is under investigation for the treatment of cocaine dependence, and recently demonstrated effectiveness for this indication in a large-scale (n = 302) clinical trial (at a high buprenorphine dose of 16 mg, but not a low dose of 4 mg).[111] [112]

Neonatal abstinence

Buprenorphine has been used in the treatment of the neonatal abstinence syndrome,[113] a condition in which newborns exposed to opioids during pregnancy demonstrate signs of withdrawal.[114] In the United States, use currently is limited to infants enrolled in a clinical trial conducted under an FDA-approved investigational new drug (IND) application. Preliminary research suggests that buprenorphine is associated with shorter time in hospital for neonates, compared to methadone.[115] An ethanolic formulation used in neonates is stable at room temperature for at least 30 days.[116]

Veterinary uses

Veterinarians administer buprenorphine for perioperative pain, particularly in cats, where its effects are similar to morphine. The drug's legal status and lower potential for human abuse makes it an attractive alternative to other opioids.[117]

It has veterinary medical use for treatment of pain in dogs and cats, as well as other animals.[118] [119] [120]

External links

Notes and References

  1. Web site: Buprenorphine Use During Pregnancy . Drugs.com . 14 October 2019 . 17 May 2020 . 10 November 2020 . https://web.archive.org/web/20201110201941/https://www.drugs.com/pregnancy/buprenorphine.html . live .
  2. Australian Public Assessment Report for Buprenorphine . . November 2019 . https://web.archive.org/web/20240320144416/https://www.tga.gov.au/sites/default/files/auspar-buprenorphine-191106.pdf . 20 March 2024 . live.
  3. Book: Bonewit-West K, Hunt AS, Applegate E . Today's Medical Assistant: Clinical and Administrative Procedures . 2012 . 571 . Elsevier Health Sciences . 9781455701506 . 16 February 2020 . 10 January 2023 . https://web.archive.org/web/20230110030031/https://books.google.com/books?id=YalYPI1KqTQC&pg=PA571 . live .
  4. Web site: Anvisa . Brazilian Health Regulatory Agency . 31 March 2023 . RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial . Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control. live . https://web.archive.org/web/20230803143925/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 . 3 August 2023 . 16 August 2023 . . pt-BR . 4 April 2023.
  5. Web site: ARCHIVED - Report Stakeholder Workshop on a National Buprenorphine Program . . 10 January 2020 . 6 December 2004 . 26 March 2020 . https://web.archive.org/web/20200326042128/https://www.canada.ca/en/health-canada/services/drugs-health-products/reports-publications/drug-products/report-stakeholder-workshop-national-buprenorphine-program-november-18-2004-health-canada.html . live .
  6. Web site: Neurological therapies . . 9 May 2018 . 13 April 2024.
  7. Web site: Subutex (buprenorphine sublingual tablets), CIII Initial U.S. Approval: 1981 . DailyMed . 26 May 2023 . 27 May 2023 . https://web.archive.org/web/20230527012727/https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=660696 . live .
  8. Web site: Sublocade- buprenorphine solution . DailyMed . 15 March 2023 . 26 May 2023 . 27 May 2023 . https://web.archive.org/web/20230527012729/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6189fb21-9432-45f8-8481-0bfaf3ccde95 . live .
  9. Web site: Butrans- buprenorphine patch, extended release . DailyMed . 26 June 2022 . 26 May 2023 . 27 May 2023 . https://web.archive.org/web/20230527015432/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=794aa355-66de-41b8-aedf-f2c40f6bc664 . live .
  10. Web site: Brixadi- buprenorphine injection . DailyMed . 21 June 2023 . 25 June 2023 . 26 June 2023 . https://web.archive.org/web/20230626054011/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5d8a8fd0-8619-422a-a664-d1d2e8970f48 . live .
  11. FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder . U.S. Food and Drug Administration . 23 May 2023 . 26 May 2023.
  12. Web site: Buvidal EPAR . European Medicines Agency (EMA) . 20 November 2018 . 10 August 2024.
  13. Mendelson J, Upton RA, Everhart ET, Jacob P, Jones RT . Bioavailability of sublingual buprenorphine . Journal of Clinical Pharmacology . 37 . 1 . 31–37 . January 1997 . 9048270 . 10.1177/009127009703700106 . 31735116 .
  14. Eriksen J, Jensen NH, Kamp-Jensen M, Bjarnø H, Friis P, Brewster D . The systemic availability of buprenorphine administered by nasal spray . The Journal of Pharmacy and Pharmacology . 41 . 11 . 803–805 . November 1989 . 2576057 . 10.1111/j.2042-7158.1989.tb06374.x . 1286222 .
  15. Web site: Buprenorphine / Naloxone Buccal Film (BUNAVAIL) C-III. September 2014. Pharmacy Benefits Management (PBM) Services. 10 February 2020. 20 October 2020. https://web.archive.org/web/20201020045302/https://www.pbm.va.gov/PBM/clinicalguidance/abbreviatedreviews/Buprenorphine_NX_Buccal_Film_BUNAVAIL_%20Abbreviated_Review.pdf. live.
  16. Web site: Bunavail (buprenorphine and naloxone buccal film), CIII Initial U.S. Approval: 2002 . DailyMed . 26 May 2023 . 27 May 2023 . https://web.archive.org/web/20230527012731/https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=657905 . live .
  17. FDA approves first buprenorphine implant for treatment of opioid dependence . U.S. Food and Drug Administration. 26 May 2016. 12 December 2017. 30 November 2017. https://web.archive.org/web/20171130112207/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm503719.htm. live.
  18. Blazes CK, Morrow JD . Reconsidering the Usefulness of Adding Naloxone to Buprenorphine . Frontiers in Psychiatry . 11 . 549272 . 11 September 2020 . 33061915 . 10.3389/fpsyt.2020.549272 . 7517938 . free .
  19. Whelan PJ, Remski K . Buprenorphine vs methadone treatment: A review of evidence in both developed and developing worlds . Journal of Neurosciences in Rural Practice . 3 . 1 . 45–50 . January 2012 . 22346191 . 3271614 . 10.4103/0976-3147.91934 . free .
  20. Web site: Buprenorphine. 15 June 2015. The Substance Abuse and Mental Health Services Administration. 14 October 2020. 26 August 2020. https://web.archive.org/web/20200826213906/https://www.samhsa.gov/medication-assisted-treatment/medications-counseling-related-conditions/buprenorphine. live.
  21. Web site: Buprenorphine use while Breastfeeding . Drugs.com . 7 February 2021 . 10 November 2020 . https://web.archive.org/web/20201110125323/https://www.drugs.com/breastfeeding/buprenorphine.html . live.
  22. Web site: Buprenorphine Hydrochloride. drugs.com. American Society of Health-System Pharmacists. 17 March 2017. 26 January 2017. 18 July 2017. https://web.archive.org/web/20170718164516/https://www.drugs.com/monograph/buprenorphine-hydrochloride.html. live.
  23. Book: Fischer J, Ganellin CR . Analogue-based Drug Discovery . 2006 . John Wiley & Sons . 9783527607495 . 528 . 29 May 2020 . 10 January 2023 . https://web.archive.org/web/20230110212258/https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA528 . live .
  24. Book: ((World Health Organization)) . World Health Organization model list of essential medicines: 22nd list (2021) . 2021 . 10665/345533 . World Health Organization . World Health Organization . Geneva . WHO/MHP/HPS/EML/2021.02 . free .
  25. Web site: The Top 300 of 2020 . ClinCalc . 7 October 2022 . 12 February 2021 . https://web.archive.org/web/20210212142534/https://clincalc.com/DrugStats/Top300Drugs.aspx . live .
  26. Web site: Buprenorphine - Drug Usage Statistics . ClinCalc . 7 October 2022 . 11 October 2022 . https://web.archive.org/web/20221011050244/https://clincalc.com/DrugStats/Drugs/Buprenorphine . live .
  27. Web site: July 2019 . Buprenorphine . live . https://web.archive.org/web/20200820141229/https://www.samhsa.gov/medication-assisted-treatment/medications-counseling-related-conditions/buprenorphine . 20 August 2020 . 9 January 2020. SAMHSA Center for Substance Abuse Treatment (CSAT).
  28. Book: Levounis P, Avery J . Patient Assessment . Renner Jr JA, Levounis P, LaRose AT . Office-based buprenorphine treatment of opioid use disorder . American Psychiatric Association Publishing . 2018 . 978-1-61537-170-9 . Arlington, VA . 1002302926 .
  29. Book: Restrepo R, Levounis P . Clinical Use of Buprenorphine . Renner Jr JA, Levounis P, LaRose AT . Office-based buprenorphine treatment of opioid use disorder . American Psychiatric Association Publishing. 2018. 978-1-61537-170-9 . Arlington, VA . 1002302926 .
  30. Web site: Naloxone Hydrochloride. The American Society of Health-System Pharmacists. 2 January 2015. live. https://web.archive.org/web/20150102115454/http://www.drugs.com/monograph/naloxone-hydrochloride.html. 2 January 2015.
  31. Sue KL, Cohen S, Tilley J, Yocheved A . A Plea From People Who Use Drugs to Clinicians: New Ways to Initiate Buprenorphine Are Urgently Needed in the Fentanyl Era . Journal of Addiction Medicine . 16 . 4 . 389–391 . January 2022 . 35020693 . 10.1097/ADM.0000000000000952 . 245925947 .
  32. Hämmig R, Kemter A, Strasser J, von Bardeleben U, Gugger B, Walter M, Dürsteler KM, Vogel M . Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method . Substance Abuse and Rehabilitation . 7 . 99–105 . 20 July 2016 . 27499655 . 4959756 . 10.2147/SAR.S109919 . free .
  33. Ahmed S, Bhivandkar S, Lonergan BB, Suzuki J . Microinduction of Buprenorphine/Naloxone: A Review of the Literature . The American Journal on Addictions . 30 . 4 . 305–315 . July 2021 . 33378137 . 10.1111/ajad.13135 . 229721826 .
  34. Gowing L, Ali R, White JM, Mbewe D . Buprenorphine for managing opioid withdrawal . The Cochrane Database of Systematic Reviews . 2017 . 2 . CD002025 . February 2017 . 28220474 . 6464315 . 10.1002/14651858.CD002025.pub5 .
  35. Lemon LS, Caritis SN, Venkataramanan R, Platt RW, Bodnar LM . Methadone Versus Buprenorphine for Opioid Use Dependence and Risk of Neonatal Abstinence Syndrome . en-US . Epidemiology . 29 . 2 . 261–268 . March 2018 . 29112519 . 5792296 . 10.1097/EDE.0000000000000780 . Methadone is associated with increased risk of neonatal abstinence syndrome compared with buprenorphine in infants exposed in utero. This association is subject to minimal bias due to unmeasured confounding by severity of addiction. .
  36. Auriacombe M, Fatséas M, Dubernet J, Daulouède JP, Tignol J . French field experience with buprenorphine . The American Journal on Addictions . 13 . Suppl 1 . S17–S28 . 2004 . 15204673 . 10.1080/10550490490440780 .
  37. Web site: Office of the Assistant Secretary for Health (OASH). 14 January 2021. HHS Expands Access to Treatment for Opioid Use Disorder . 5 January 2022. HHS.gov. 25 January 2022. https://web.archive.org/web/20220125001024/https://www.hhs.gov/about/news/2021/01/14/hhs-expands-access-to-treatment-for-opioid-use-disorder.html. live.
  38. Removing The X-Waiver Is One Small Step Toward Increasing Treatment Of Opioid Use Disorder, But Great Leaps Are Needed . Health Affairs Forefront . 5 January 2022 . Stringfellow EJ, Humphreys K, Jalali MS . 2021 . 10.1377/forefront.20210419.311749 . 14 October 2022 . https://web.archive.org/web/20221014051149/https://www.healthaffairs.org/do/10.1377/forefront.20210419.311749/full/ . live .
  39. Web site: Butrans Medication Guide. Butrans Medication Guide. Purdue Pharma L.P.. 7 July 2014. 14 July 2014. https://web.archive.org/web/20140714150342/http://app.purduepharma.com/xmlpublishing/pi.aspx?id=b&medguide=1. live.
  40. "Book: http://www.dea.gov/pubs/abuse/4-narc.htm . Ch. 4 Narcotics: Narcotics Treatment Drugs: Buprenorphine . Drugs of Abuse . Drug Enforcement Administration . U.S. Department of Justice . 2005 . https://web.archive.org/web/20061102144614/http://www.dea.gov/pubs/abuse/4-narc.htm . 2 November 2006 .
  41. Web site: Opioid Conversion Guide. February 2016. Department of Health, Government of Western Australia. 10 February 2020. 18 April 2020. https://web.archive.org/web/20200418072615/https://ww2.health.wa.gov.au/~/media/Files/Corporate/general%20documents/Health%20Networks/WA%20Cancer%20and%20Palliative%20Care/How-to-use-the-Opioid-Conversion-Guide.pdf. live.
  42. Cote J, Montgomery L . Sublingual buprenorphine as an analgesic in chronic pain: a systematic review . Pain Medicine . 15 . 7 . 1171–1178 . July 2014 . 24995716 . 10.1111/pme.12386 . free .
  43. Khanna IK, Pillarisetti S . Buprenorphine - an attractive opioid with underutilized potential in treatment of chronic pain . Journal of Pain Research . 8 . 859–870 . 2015 . 26672499 . 4675640 . 10.2147/JPR.S85951 . free .
  44. Budd K, Raffa RB. (eds.) Buprenorphine – The unique opioid analgesic. Thieme, 200,
  45. Tchikrizov V, Richert AC, Bhardwaj SB . Case of buprenorphine-associated central sleep apnea resolving with dose reduction . Journal of Opioid Management . 18 . 4 . 391–394 . 1 July 2022 . 36052936 . 10.5055/jom.2022.0732 . 251959885 .
  46. DeVido J, Connery H, Hill KP . Sleep-disordered breathing in patients with opioid use disorders in long-term maintenance on buprenorphine-naloxone: A case series . Journal of Opioid Management . 11 . 4 . 363–366 . 1 July 2015 . 26312963 . 10.5055/jom.2015.0285 . 4754775 .
  47. Web site: Buprenorphine. www.samhsa.gov. 3 December 2017. 31 May 2016. 9 July 2021. https://web.archive.org/web/20210709105557/https://www.samhsa.gov/medication-assisted-treatment/medications-counseling-related-conditions/buprenorphine. live.
  48. White LD, Hodge A, Vlok R, Hurtado G, Eastern K, Melhuish TM . Efficacy and adverse effects of buprenorphine in acute pain management: systematic review and meta-analysis of randomised controlled trials . British Journal of Anaesthesia . 120 . 4 . 668–678 . April 2018 . 29576108 . 10.1016/j.bja.2017.11.086 . free .
  49. Alford DP, Compton P, Samet JH . Acute pain management for patients receiving maintenance methadone or buprenorphine therapy . Annals of Internal Medicine . 144 . 2 . 127–134 . January 2006 . 16418412 . 1892816 . 10.7326/0003-4819-144-2-200601170-00010 .
  50. Disha Mehta, Vinod Thomas, Jacinta Johnson, Brooke Scott, Sandra Cortina, Landon Berger. 2020 Continuation of Buprenorphine to Facilitate Postoperative Pain Management for Patients on Buprenorphine Opioid Agonist Therapy. 23;E163-E174. https://www.painphysicianjournal.com/current/pdf?article=NzAzMQ%3D%3D&journal=125
  51. Web site: PDSP Ki Database . Psychoactive Drug Screening Program (PDSP) . Roth BL, Driscol J . Bryan Roth . University of North Carolina at Chapel Hill and the United States National Institute of Mental Health . 14 August 2017 . 29 August 2021 . https://web.archive.org/web/20210829111648/https://kidbdev.med.unc.edu/databases/pdsp.php?knowID=0&kiKey=&receptorDD=&receptor=&speciesDD=&species=&sourcesDD=&source=&hotLigandDD=&hotLigand=&testLigandDD=&testFreeRadio=testFreeRadio&testLigand=buprenorphine&referenceDD=&reference=&KiGreater=&KiLess=&kiAllRadio=all&doQuery=Submit+Query . live .
  52. Toll L, Berzetei-Gurske IP, Polgar WE, Brandt SR, Adapa ID, Rodriguez L, Schwartz RW, Haggart D, O'Brien A, White A, Kennedy JM, Craymer K, Farrington L, Auh JS . Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications . NIDA Research Monograph . 178 . 440–466 . March 1998 . 9686407 .
  53. Khroyan TV, Polgar WE, Jiang F, Zaveri NT, Toll L . Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists . The Journal of Pharmacology and Experimental Therapeutics . 331 . 3 . 946–953 . December 2009 . 19713488 . 2784721 . 10.1124/jpet.109.156711 .
  54. Khroyan TV, Wu J, Polgar WE, Cami-Kobeci G, Fotaki N, Husbands SM, Toll L . BU08073 a buprenorphine analogue with partial agonist activity at μ-receptors in vitro but long-lasting opioid antagonist activity in vivo in mice . British Journal of Pharmacology . 172 . 2 . 668–680 . January 2015 . 24903063 . 4292977 . 10.1111/bph.12796 .
  55. Negus SS, Bidlack JM, Mello NK, Furness MS, Rice KC, Brandt MR . Delta opioid antagonist effects of buprenorphine in rhesus monkeys . Behavioural Pharmacology . 13 . 7 . 557–570 . November 2002 . 12409994 . 10.1097/00008877-200211000-00005 .
  56. Lutfy K, Cowan A . Buprenorphine: a unique drug with complex pharmacology . Current Neuropharmacology . 2 . 4 . 395–402 . October 2004 . 18997874 . 2581407 . 10.2174/1570159043359477 .
  57. Book: Freye E . Opioid Agonists, Antagonists and Mixed Narcotic Analgesics. Interaction of Mixed Agonist-Antagonists with Different Receptor Sites Using Nalbuphine as a Model Substance. 1987. 67–78. 10.1007/978-3-642-71854-0_6. 978-3-540-17471-4.
  58. Hutchinson MR, Zhang Y, Shridhar M, Evans JH, Buchanan MM, Zhao TX, Slivka PF, Coats BD, Rezvani N, Wieseler J, Hughes TS, Landgraf KE, Chan S, Fong S, Phipps S, Falke JJ, Leinwand LA, Maier SF, Yin H, Rice KC, Watkins LR . Evidence that opioids may have toll-like receptor 4 and MD-2 effects . Brain, Behavior, and Immunity . 24 . 1 . 83–95 . January 2010 . 19679181 . 2788078 . 10.1016/j.bbi.2009.08.004 .
  59. Codd EE, Shank RP, Schupsky JJ, Raffa RB . Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception . The Journal of Pharmacology and Experimental Therapeutics . 274 . 3 . 1263–1270 . September 1995 . 7562497 .
  60. Leffler A, Frank G, Kistner K, Niedermirtl F, Koppert W, Reeh PW, Nau C . Local anesthetic-like inhibition of voltage-gated Na(+) channels by the partial μ-opioid receptor agonist buprenorphine . Anesthesiology . 116 . 6 . 1335–1346 . June 2012 . 22504149 . 10.1097/ALN.0b013e3182557917 . free .
  61. Gudin J, Fudin J . A Narrative Pharmacological Review of Buprenorphine: A Unique Opioid for the Treatment of Chronic Pain . Pain and Therapy . 9 . 1 . 41–54 . June 2020 . 31994020 . 7203271 . 10.1007/s40122-019-00143-6 .
  62. Khanna IK, Pillarisetti S . Buprenorphine - an attractive opioid with underutilized potential in treatment of chronic pain . Journal of Pain Research . 8 . 859–870 . 2015 . 26672499 . 4675640 . 10.2147/JPR.S85951 . free .
  63. Madison CA, Eitan S . Buprenorphine: prospective novel therapy for depression and PTSD . Psychological Medicine . 50 . 6 . 881–893 . April 2020 . 32204739 . 10.1017/S0033291720000525 . 214630021 .
  64. Stefanowski B, Antosik-Wójcińska A, Święcicki Ł . The use of buprenorphine in the treatment of drug-resistant depression - an overview of the studies . Psychiatria Polska . 54 . 2 . 199–207 . April 2020 . 32772054 . 10.12740/PP/102658 . free .
  65. Carlezon WA, Béguin C, Knoll AT, Cohen BM . Kappa-opioid ligands in the study and treatment of mood disorders . Pharmacology & Therapeutics . 123 . 3 . 334–343 . September 2009 . 19497337 . 2740476 . 10.1016/j.pharmthera.2009.05.008 .
  66. Book: Benzon H, Raja S, Fishman S, Liu SS, Cohen SP. Essentials of Pain Medicine E-Book. 2017. Elsevier Health Sciences. 9780323445412. 382. 29 May 2020. 14 January 2023. https://web.archive.org/web/20230114153757/https://books.google.com/books?id=w3g4DwAAQBAJ&pg=PA382. live.
  67. Jacob JJ, Michaud GM, Tremblay EC . Mixed agonist-antagonist opiates and physical dependence . British Journal of Clinical Pharmacology . 7 . Suppl 3 . 291S–296S . 1979 . 572694 . 1429306 . 10.1111/j.1365-2125.1979.tb04703.x .
  68. Kress HG . Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine . European Journal of Pain . 13 . 3 . 219–230 . March 2009 . 18567516 . 10.1016/j.ejpain.2008.04.011 . 8243410 .
  69. Robinson SE . Buprenorphine: an analgesic with an expanding role in the treatment of opioid addiction . CNS Drug Reviews . 8 . 4 . 377–390 . 2002 . 12481193 . 6741692 . 10.1111/j.1527-3458.2002.tb00235.x .
  70. Book: Ruiz P, Strain EC . Lowinson and Ruiz's Substance Abuse: A Comprehensive Textbook . 2011 . Lippincott Williams & Wilkins . 978-1-60547-277-5 . 439 . 14 March 2016 . 14 January 2023 . https://web.archive.org/web/20230114153759/https://books.google.com/books?id=w4ZUJAdleTsC&pg=PA439 . live .
  71. Book: Bidlack JM . Mixed κ/μ partial opioid agonists as potential treatments for cocaine dependence . Mixed Kappa/Mu Partial Opioid Agonists as Potential Treatments for Cocaine Dependence . Advances in Pharmacology . 69 . 387–418 . 2014 . 24484983 . 10.1016/B978-0-12-420118-7.00010-X . 9780124201187 .
  72. Ehrich E, Turncliff R, Du Y, Leigh-Pemberton R, Fernandez E, Jones R, Fava M . Evaluation of opioid modulation in major depressive disorder . Neuropsychopharmacology . 40 . 6 . 1448–1455 . May 2015 . 25518754 . 4397403 . 10.1038/npp.2014.330 .
  73. Coller JK, Christrup LL, Somogyi AA . Role of active metabolites in the use of opioids . European Journal of Clinical Pharmacology . 65 . 2 . 121–139 . February 2009 . 18958460 . 10.1007/s00228-008-0570-y . 9977741 .
  74. Mizoguchi H, Wu HE, Narita M, Hall FS, Sora I, Uhl GR, Nagase H, Tseng LF . Antagonistic property of buprenorphine for putative epsilon-opioid receptor-mediated G-protein activation by beta-endorphin in pons/medulla of the mu-opioid receptor knockout mouse . Neuroscience . 115 . 3 . 715–721 . 2002 . 12435410 . 10.1016/s0306-4522(02)00486-4 . 54316989 .
  75. Mizoguchi H, Spaulding A, Leitermann R, Wu HE, Nagase H, Tseng LF . Buprenorphine blocks epsilon- and micro-opioid receptor-mediated antinociception in the mouse . The Journal of Pharmacology and Experimental Therapeutics . 306 . 1 . 394–400 . July 2003 . 12721333 . 10.1124/jpet.103.048835 . 44036890 .
  76. Xu J, Xu M, Hurd YL, Pasternak GW, Pan YX . Isolation and characterization of new exon 11-associated N-terminal splice variants of the human mu opioid receptor gene . Journal of Neurochemistry . 108 . 4 . 962–972 . February 2009 . 19077058 . 2727151 . 10.1111/j.1471-4159.2008.05833.x .
  77. Grinnell S et al. (2014): Buprenorphine analgesia requires exon 11-associated mu opioid receptor splice variants. The FASEB Journal
  78. Book: Miller PM . Biological Research on Addiction . Comprehensive Addictive Behaviors and Disorders . 2 . Colasanti A, Lingford-Hughes A, Nutt D . Opioids Neuroimaging . 2013 . 675–687 . Elsevier . 10.1016/B978-0-12-398335-0.00066-2 . 9780123983350 .
  79. Zubieta J, Greenwald MK, Lombardi U, Woods JH, Kilbourn MR, Jewett DM, Koeppe RA, Schuster CR, Johanson CE . Buprenorphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: a preliminary study . Neuropsychopharmacology . 23 . 3 . 326–334 . September 2000 . 10942856 . 10.1016/S0893-133X(00)00110-X . 27350905 . free .
  80. Greenwald MK, Johanson CE, Moody DE, Woods JH, Kilbourn MR, Koeppe RA, Schuster CR, Zubieta JK . Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers . Neuropsychopharmacology . 28 . 11 . 2000–2009 . November 2003 . 12902992 . 10.1038/sj.npp.1300251 . 20773085 . free .
  81. Greenwald M, Johanson CE, Bueller J, Chang Y, Moody DE, Kilbourn M, Koeppe R, Zubieta JK . Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices . Biological Psychiatry . 61 . 1 . 101–110 . January 2007 . 16950210 . 10.1016/j.biopsych.2006.04.043 . 46105421 .
  82. Book: Doweiko HE . Concepts of Chemical Dependency. 14 March 2014. Cengage Learning. 978-1-285-45717-8. 149–.
  83. Book: USP DI.. 1997. United States Pharmacopeial Convention. 9780913595947.
  84. Moody DE, Fang WB, Lin SN, Weyant DM, Strom SC, Omiecinski CJ . Effect of rifampin and nelfinavir on the metabolism of methadone and buprenorphine in primary cultures of human hepatocytes . Drug Metabolism and Disposition . 37 . 12 . 2323–2329 . December 2009 . 19773542 . 2784702 . 10.1124/dmd.109.028605 .
  85. Yassen A, Kan J, Olofsen E, Suidgeest E, Dahan A, Danhof M . Pharmacokinetic-pharmacodynamic modeling of the respiratory depressant effect of norbuprenorphine in rats . The Journal of Pharmacology and Experimental Therapeutics . 321 . 2 . 598–607 . May 2007 . 17283225 . 10.1124/jpet.106.115972 . 11921738 .
  86. Huang P, Kehner GB, Cowan A, Liu-Chen LY . Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist . The Journal of Pharmacology and Experimental Therapeutics . 297 . 2 . 688–695 . May 2001 . 11303059 .
  87. Brown SM, Campbell SD, Crafford A, Regina KJ, Holtzman MJ, Kharasch ED . P-glycoprotein is a major determinant of norbuprenorphine brain exposure and antinociception . The Journal of Pharmacology and Experimental Therapeutics . 343 . 1 . 53–61 . October 2012 . 22739506 . 3464040 . 10.1124/jpet.112.193433 .
  88. Brown SM, Holtzman M, Kim T, Kharasch ED . Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active . Anesthesiology . 115 . 6 . 1251–1260 . December 2011 . 22037640 . 3560935 . 10.1097/ALN.0b013e318238fea0 .
  89. Heel RC, Brogden RN, Speight TM, Avery GS . Buprenorphine: a review of its pharmacological properties and therapeutic efficacy . Drugs . 17 . 2 . 81–110 . February 1979 . 378645 . 10.2165/00003495-197917020-00001 . 19577410 .
  90. Book: Baselt R . 2008 . Disposition of Toxic Drugs and Chemicals in Man . 8th . Biomedical Publications . Foster City, CA . 190–192 . 978-0962652370.
  91. Web site: IMPORTANT SAFETY INFORMATION. 25 June 2016. https://web.archive.org/web/20190318223620/https://www.suboxone.com/medical-treatment/side-effects-adverse-events. 18 March 2019. dead.
  92. Campbell ND, Lovell AM . The history of the development of buprenorphine as an addiction therapeutic . Annals of the New York Academy of Sciences . 1248 . 1 . 124–139 . February 2012 . 22256949 . 10.1111/j.1749-6632.2011.06352.x . 28395410 . 2012NYASA1248..124C .
  93. Book: Problems of Drug Dependence, 1998: Proceedings of the 66th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc. . Louis S. Harris . NIDA Research Monograph 179 . 1998 . 5 August 2012 . https://web.archive.org/web/20161203055853/http://rzbl04.biblio.etc.tu-bs.de:8080/docportal/servlets/MCRFileNodeServlet/DocPortal_derivate_00001868/NIDA179.pdf . 3 December 2016 . dead .
  94. McCormick CG . http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/20732,20733ltr.pdf . Reckitt Benckiser . Subutex and Suboxone Approval Letter]. . U.S. Food and Drug Administration . 8 October 2002 .
  95. , 7 October 2002
  96. Web site: Quotas – Conversion Factors for Controlled Substances . Deadiversion.usdoj.gov . 7 November 2016 . 2 March 2016 . https://web.archive.org/web/20160302162948/http://deadiversion.usdoj.gov/quotas/conv_factor/index.html . dead .
  97. Web site: Drug Addiction Treatment Act of 2000 . https://web.archive.org/web/20130304203025/http://buprenorphine.samhsa.gov/titlexxxv.html . 4 March 2013 . SAMHSA, U.S. Department of Health & Human Services .
  98. Web site: The National Alliance of Advocates for Buprenorphine Treatment . naabt.org . 19 May 2013 . 12 November 2020 . https://web.archive.org/web/20201112022606/http://www.naabt.org/30_patient_limit.cfm . live .
  99. Web site: Obama administration's change on buprenorphine policy . Business Insider . 6 July 2016 . 7 November 2016 . 18 March 2020 . https://web.archive.org/web/20200318181953/https://www.businessinsider.com/obama-buprenorphine-suboxone-policy-2016-7 . live .
  100. HHS Expands Access to Treatment for Opioid Use Disorder . US Deptartment of Health and Human Services . 14 January 2021 . 14 January 2021 . 14 January 2021 . https://web.archive.org/web/20210114212923/https://www.hhs.gov/about/news/2021/01/14/hhs-expands-access-to-treatment-for-opioid-use-disorder.html . dead .
  101. Web site: In national first, N.J. program will let paramedics administer buprenorphine. 26 June 2019. STAT. 21 November 2019. 3 October 2019. https://web.archive.org/web/20191003145623/https://www.statnews.com/2019/06/26/new-jersey-paramedics-buprenorphine/. live.
  102. Web site: Suboxone EU Approval . Ema.europa.eu . 7 November 2016 . 24 December 2016 . https://web.archive.org/web/20161224231647/http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Fhuman%2Fmedicines%2F000697%2Fhuman_med_001067.jsp&mid=WC0b01ac058001d124 . live .
  103. Poloméni P, Schwan R . Management of opioid addiction with buprenorphine: French history and current management . International Journal of General Medicine . 7 . 143–148 . 3 March 2014 . 24623988 . 3949694 . 10.2147/IJGM.S53170 . free .
  104. FDA approves first once-monthly buprenorphine injection, a medication-assisted treatment option for opioid use disorder. U.S. Food and Drug Administration. 30 November 2017. 5 December 2017. 3 December 2017. https://web.archive.org/web/20171203063547/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm587312.htm. live.
  105. News: Indivior drug to fight opioid addiction approved by U.S. FDA. 2017. Reuters. 5 December 2017. 5 December 2017. https://web.archive.org/web/20171205093202/https://www.reuters.com/article/us-indivior-opioids/indivior-drug-to-fight-opioid-addiction-approved-by-u-s-fda-idUSKBN1DV47M. live.
  106. Web site: Sublocade Now Available for Moderate-to-Severe Opioid Use Disorder. 1 March 2018. MPR. 23 September 2019. 23 September 2019. https://web.archive.org/web/20190923021822/https://www.empr.com/home/news/sublocade-now-available-for-moderate-to-severe-opioid-use-disorder/. live.
  107. Web site: Buprenorphine. Martindale: The Complete Drug Reference. Pharmaceutical Press. London, UK. 14 January 2014. 6 April 2014. 28 August 2021. https://web.archive.org/web/20210828013027/https://about.medicinescomplete.com/wp-content/themes/mc-marketing/assets/images/favicons-tiles/favicon.ico. live.
  108. Ahmed S, Bhivandkar S, Lonergan BB, Suzuki J . Microinduction of Buprenorphine/Naloxone: A Review of the Literature . Am J Addict . 30 . 4 . 305–315 . July 2021 . 33378137 . 10.1111/ajad.13135 . 229721826 . Review.
  109. Stanciu CN, Glass OM, Penders TM . Use of Buprenorphine in treatment of refractory depression-A review of current literature . Asian Journal of Psychiatry . 26 . 94–98 . April 2017 . 28483102 . 10.1016/j.ajp.2017.01.015 .
  110. Ragguett RM, Rong C, Rosenblat JD, Ho RC, McIntyre RS . Pharmacodynamic and pharmacokinetic evaluation of buprenorphine + samidorphan for the treatment of major depressive disorder . Expert Opinion on Drug Metabolism & Toxicology . 14 . 4 . 475–482 . April 2018 . 29621905 . 10.1080/17425255.2018.1459564 . 4633923 .
  111. Ling W, Hillhouse MP, Saxon AJ, Mooney LJ, Thomas CM, Ang A, Matthews AG, Hasson A, Annon J, Sparenborg S, Liu DS, McCormack J, Church S, Swafford W, Drexler K, Schuman C, Ross S, Wiest K, Korthuis PT, Lawson W, Brigham GS, Knox PC, Dawes M, Rotrosen J . Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study . Addiction . 111 . 8 . 1416–1427 . August 2016 . 26948856 . 4940267 . 10.1111/add.13375 .
  112. Web site: Alkermes Presents Positive Clinical Data of ALKS 5461 at 52nd Annual New Clinical Drug Evaluation Unit Meeting . Reuters . 2012 . 30 June 2017 . 24 September 2015 . https://web.archive.org/web/20150924164224/http://www.reuters.com/article/2012/05/29/idUS197896+29-May-2012+BW20120529 . dead .
  113. Kraft WK, Gibson E, Dysart K, Damle VS, Larusso JL, Greenspan JS, Moody DE, Kaltenbach K, Ehrlich ME . Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial . Pediatrics . 122 . 3 . e601–e607 . September 2008 . 18694901 . 2574639 . 10.1542/peds.2008-0571 .
  114. Kraft WK, van den Anker JN . Pharmacologic management of the opioid neonatal abstinence syndrome . Pediatric Clinics of North America . 59 . 5 . 1147–1165 . October 2012 . 23036249 . 4709246 . 10.1016/j.pcl.2012.07.006 .
  115. Tran TH, Griffin BL, Stone RH, Vest KM, Todd TJ . Methadone, Buprenorphine, and Naltrexone for the Treatment of Opioid Use Disorder in Pregnant Women . Pharmacotherapy . 37 . 7 . 824–839 . July 2017 . 28543191 . 10.1002/phar.1958 . Currently, methadone and buprenorphine are both widely used as the backbone of MAT [medication-assisted treatment]. The distinguishing outcomes in studies among these two opioid agonists are that infants exposed to buprenorphine in clinical trials required shorter treatment duration, less medication to treat the NAS symptoms and experienced shorter hospitalizations compared to infants exposed to methadone. A caveat to these findings is that some of the supporting data were based on using buprenorphine in combination with naloxone instead of buprenorphine as a single agent. . 13772333 .
  116. Anagnostis EA, Sadaka RE, Sailor LA, Moody DE, Dysart KC, Kraft WK . Formulation of buprenorphine for sublingual use in neonates . The Journal of Pediatric Pharmacology and Therapeutics . 16 . 4 . 281–284 . October 2011 . 22768012 . 3385042 . 10.5863/1551-6776-16.4.281 .
  117. Web site: Martinez M . Options in perioperative analgesia: buprenorphine v. methadone . Veterinary Practice . May 2014 . 19 January 2022 . 19 January 2022 . https://web.archive.org/web/20220119231147/https://www.veterinary-practice.com/article/options-in-perioperative-analgesia-buprenorphine-v-methadone . live .
  118. Web site: Buprenorphine . Claude A . June 2015 . cliniciansbrief.com . 25 February 2017 . https://web.archive.org/web/20170516195037/http://www.cliniciansbrief.com/sites/default/files/attachments/MEDS_Bupreorphine.pdf . 16 May 2017 . dead .
  119. Book: Kukanich B, Papich MG . Riviere JE, Papich MG . Veterinary Pharmacology and Therapeutics . https://books.google.com/books?id=xAPa4WDzAnQC&pg=PA324 . 9th . 14 May 2013 . John Wiley & Sons . 9781118685907 . 323–325 . Opioid Analgesic Drugs . 25 December 2021 . 1 May 2023 . https://web.archive.org/web/20230501050348/https://books.google.com/books?id=xAPa4WDzAnQC&pg=PA324 . live .
  120. Steagall PV, Ruel HL, Yasuda T, Monteiro BP, Watanabe R, Evangelista MC, Beaudry F . Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial . BMC Veterinary Research . 16 . 1 . 154 . May 2020 . 32448336 . 7245774 . 10.1186/s12917-020-02364-w . free .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Buprenorphine".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.